Why Motorsport Games Shares Are Trading Lower By Over 10 Here Are 20 Stocks Moving Premarket - Berkshir - Benzinga
NBSEDelisted Stock | USD 1.62 0.17 9.50% |
About 62% of NeuBase Therapeutics' investor base is looking to short. The analysis of current outlook of investing in NeuBase Therapeutics suggests that many traders are alarmed regarding NeuBase Therapeutics' prospects. The current market sentiment, together with NeuBase Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use NeuBase Therapeutics stock news signals to limit their universe of possible portfolio assets.
NeuBase |
Why Motorsport Games Shares Are Trading Lower By Over 10 Here Are 20 Stocks Moving Premarket - Berkshir Benzinga
Read at news.google.com
NeuBase Therapeutics Fundamental Analysis
We analyze NeuBase Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
NeuBase Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
NeuBase Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuBase Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics with similar companies.
Peers
NeuBase Therapeutics Related Equities
PHGE | Biomx | 18.33 | ||||
GLUE | Monte Rosa | 13.72 | ||||
IMMX | Immix Biopharma | 7.11 | ||||
CMPX | Compass Therapeutics | 4.49 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
IVA | Inventiva | 1.12 | ||||
SONN | Sonnet Biotherapeutics | 2.28 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
NAMS | NewAmsterdam Pharma | 4.57 | ||||
CNSP | Cns Pharmaceuticals | 8.33 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |